Evidence map›Paper›PMID 40263357›Full record

ArticleNPJ Regenerative medicine2025

Combinatorial extracellular matrix tissue chips for optimizing mesenchymal stromal cell microenvironment and manufacturing.

Ishita Jain, Alex H P Chan, Guang Yang, Hao He, Johnny Lam, Kyung Sung, Ngan F Huang

Abstract read
In one paragraph

Article in NPJ Regenerative medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ishita Jain *Department of Cardiothoracic Surgery, Stanford University, Stanford, CA, 94305, USA.
Alex H P Chan *Department of Cardiothoracic Surgery, Stanford University, Stanford, CA, 94305, USA.ORCID http://orcid.org/0000-0002-1244-7673
Guang YangDepartment of Cardiothoracic Surgery, Stanford University, Stanford, CA, 94305, USA.
Hao HeDepartment of Cardiothoracic Surgery, Stanford University, Stanford, CA, 94305, USA.
Johnny LamCenter for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, 20993, USA.
Kyung SungCenter for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, 20993, USA.ORCID http://orcid.org/0000-0001-9664-6399
Ngan F HuangDepartment of Cardiothoracic Surgery, Stanford University, Stanford, CA, 94305, USA. ngantina@stanford.edu.ORCID http://orcid.org/0000-0003-2298-6790

Funding

Development of a Bioengineered Therapeutic Device for the Prevention of LymphedemaR01CA285372 · NCI · PALO ALTO VETERANS INSTIT FOR RESEARCH · PI Ngan F. Huang, Michael Vitoldovich Paukshto · 2024 to 2026
$1.6M
Engineered matrix microarrays to enhance the regenerative potential of iPSC-derived endothelial cellsR01HL142718 · NHLBI · STANFORD UNIVERSITY · PI HEILSHORN, SARAH C, HUANG, NGAN F. · 2018 to 2021
$1.6M
Biomaterials for delivery and maintenance of tip endothelial cellsR21HL172096 · NHLBI · UNIVERSITY OF CALIFORNIA, MERCED · PI HUANG, NGAN F., MCCLOSKEY, KARA E · 2024 to 2025
$643k
Novel Highly Regenerative and Scalable Progenitor Cell Exosomes for Treating Peripheral Artery DiseaseR41HL170875 · NHLBI · SERINA THERAPEUTICS, INC. · PI HUANG, NGAN F., LEE, JI EUN · 2023 to 2023
$341k
American Heart Association (American Heart Association, Inc.) 24POST1186485BLRD VA I01 BX004259BLRD VA I01 BX006882BLRD VA IK6 BX006309FDA HHS U01 FD005978National Science Foundation (NSF) 1829534 and 2227614NCI NIH HHS R01 CA285372NHLBI NIH HHS R01 HL142718NHLBI NIH HHS R21 HL172096NHLBI NIH HHS R41 HL170875RRD VA I21 RX004898U.S. Department of Health & Human Services | National Institutes of Health (NIH) (R01 HL142718, R01CA285372, R41HL170875, and R21 HL172096U.S. Department of Health & Human Services | U.S. Food and Drug Administration (U.S. Food & Drug Administration) U01FD005978U.S. Department of Veterans Affairs (Department of Veterans Affairs) 1I01BX004259 and RX004898 and IK6 BX006309
6 · The paper itself

Abstract

Despite the therapeutic potential of mesenchymal stromal cells (MSC), there is limited understanding of optimal extracellular matrix (ECM) environments to manufacture these cells. We developed tissue chips to study the effects of multi-factorial ECM environments under manufacturable stiffness ranges and multi-component ECM compositions. Manufacturing qualities of cell expansion potential, immunomodulation, and differentiation capacity were examined. The results show stiffness effects, with 900 kPa substrates supporting higher proliferation and osteogenic differentiation, along with anti-inflammatory IL-10 expression, whereas 150 kPa substrates promoted adipogenic differentiation at 150 kPa, suggesting that optimal ECM environments may differ based on manufacturing goals. ECM biochemistries containing fibronectin and laminin further modulated MSC manufacturing qualities across various stiffnesses. Proteomic and transcriptomic analyses revealed unique ECM combinations that induced higher levels of angiogenic and immunomodulatory cytokines, compared to single factor ECMs. These findings demonstrate that optimized ECM environments enhance MSC manufacturing quality.

Identifiers

PMID40263357
PMCPMC12015357

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.